In this episode, I am joined by specialty pharmacist Dr. Michaela Wachal, PharmD, CSP, to discuss the safety concerns regarding aluminum adjuvants used in vaccines. We explore adjuvant levels present in vaccinations that exceed the FDA’s stated safety limits, differences in bioavailability between ingested vs. injected aluminum, and research findings showing elevated aluminum levels in post-mortem brain tissue of individuals with autism and other neurodegenerative disorders. This conversation emphasizes the importance of transparency, informed consent, and continued research into aluminum exposure.